Risk Factors for Hepatotoxicity in HIV-1--Infected Patients Receiving Ritonavir and Saquinavir with or without Stavudine
Authors:
- E. H. GisolfEGE. H. Gisolf
- for the Prometheus Study GroupFGfor the Prometheus Study Group
Open Access
- 15 November 2000
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 31 (5) , 1234-1239
Abstract
Liver enzyme elevation (LEE) is commonly observed after combination antiretroviral therapy (ARVT) for HIV infection is begun. Potential risk factorsKeywords
This publication has 17 references indexed in Scilit:
- Hepatotoxicity Associated With Antiretroviral Therapy in Adults Infected With Human Immunodeficiency Virus and the Role of Hepatitis C or B Virus InfectionJAMA, 2000
- Hepatitis C in an urban population infected with the human immunodeficiency virusAIDS, 1999
- Persistence of Viremia and the Importance of Long–Term Follow–Up After Acute Hepatitis C InfectionHepatology, 1999
- Hepatotoxicity after introduction of highly active antiretroviral therapyAIDS, 1998
- Hepatitis B Virus InfectionNew England Journal of Medicine, 1997
- Restoration of immunity to chronic hepatitis B infection in HIV-infected patient on protease inhibitorThe Lancet, 1997
- Emergence of multiple drug-resistant Vibrio cholerae 01 in San Pedro Sula, HondurasThe Lancet, 1997
- Undiagnosed hepatitis C virus infection in hemodialysis patients: Value of HCV RNA and liver enzyme levelsKidney International, 1996
- Treatment of HIV InfectionDrug Safety, 1996
- Fecal hemoglobin excretion in elderly patients with atrial fibrillation: combined aspirin and low-dose warfarin vs conventional warfarin therapyArchives of internal medicine (1960), 1996